CANRIB 150 MG

Olaparib is linked in the source record to Ovarian; Breast; Pancreatic; Prostate, with the principal indications stated as BRCA-mutated ovarian/fallopian tube/primary peritoneal cancer; HER2-negative germline BRCA-mutated breast cancer; BRCA/HRR-mutated prostate and pancreatic cancer in selected settings. Its action is described as follows: Inhibits PARP-mediated DNA repair and traps PARP on DNA, producing synthetic lethality in homologous-recombination deficient cells. Its database role extends across ovarian, breast, pancreatic, and prostate cancer settings, with BRCA or broader homologous-recombination repair biology appearing where specified. The treatment interferes with PARP-dependent DNA-repair processes, making tumor DNA-repair biology an important part of treatment selection. Pharmacologically, it is a parp1/2 inhibitor and is categorized as Targeted Therapy; PARP Inhibitor. The regimen field identifies Olaparib maintenance; olaparib + bevacizumab; olaparib + endocrine therapy in selected settings. The clinical importance of those combinations is that treatment partners can determine how the medicine is positioned within a larger oncology program. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. The indication should be read as a complete clinical statement, particularly where it contains receptor, mutation, stage, prior-treatment, or disease-status requirements. A class label alone cannot establish that a drug is appropriate for a particular patient or tumor. No individualized dose, dose adjustment, or administration instruction is included.